Correct usage and dosage of tucatinib/tucatinib

Tucatinib/The standard recommended dose of Tucatinib (Tucatinib) for the treatment of breast cancer and colorectal cancer is 300 mg orally twice a day, each time and needs to be continued until disease progression or intolerable toxicity occurs. Tucatinib is often used in combination with other drugs to enhance the anti-tumor effect in HER2-positive breast cancer. The most commonly used combination regimen is combined with trastuzumab and capecitabine. The recommended dose of capecitabine is 1000 mg/m², taken orally twice a day and needs to be taken within 30 minutes after meals. Combination therapy can not only improve systemic efficacy, but also control brain metastases to a certain extent. It is an important treatment strategy for patients with advanced breast cancer.

Patients should strictly follow clinical guidelines when using tucatinib and maintain fixed dosage times and intervals to maintain stable blood concentration. Liver function, blood indicators, and potential adverse reactions need to be closely monitored during medication, including diarrhea, fatigue, elevated liver enzymes, etc. If serious side effects occur, you should contact your doctor promptly to adjust the dose or take symptomatic treatment measures. Tucatinib is an oral preparation, which is easy to manage at home, but long-term treatment still requires the guidance of a doctor to ensure a balance between efficacy and safety.

In addition, the drug may interact with other drugs or diet. For example, certainCYP3A4 inhibitors or inducers may affect blood concentration, thereby changing the efficacy or increasing the risk of side effects. Therefore, patients should inform their doctors in detail about all the drugs they are taking and have their blood and liver function checked regularly. Taken together, correct dose control, reasonable combination regimen and regular monitoring are the keys to maximizing the efficacy of tucatinib and reducing adverse reactions. With the accumulation of more clinical data in the future, the scope of application of tucatinib in the treatment of HER2-positive breast cancer will be further clarified, especially in patients with brain metastases, which will show significant advantages.

Reference materials:https://www.tukysa.com/